Clinical Trials Information System now supports submission, assessment and oversight of all trials in the EU. EMA opinion for ivermectin and albendazole supports global efforts to eliminate widespread infections. Eight new medicines recommended for approval; one positive opinion for a medicine intended for use outside the EU. The extensive use of azole fungicides azoles , particularly in some agricultural and horticultural practices, can increase the risk of Aspergillus fungi developing resistance to essential antifungal treatments.
This significant finding is highlighted in a report by the five EU health and environment agencies, with support from the European Reporting of medicine shortages by marketing authorisation holders and regulators in one single platform. Public health threats. See overview. New EMA video on how to manage and prevent medicine shortages. Regulators, healthcare professionals and consumers working together.
Clinical Trials Regulation becomes fully applicable. End of three-year transition to the Clinical Trials Information System. Human medicines committee meeting: January highlights. EU agencies publish first joint report on azole fungicide resistance to treatment. Health and environment agencies collaborate under One Health approach.
European Shortages Monitoring Platform becomes fully operational. Platform enables reporting on supply, demand and availability of medicines. EMA celebrates 30 years of progress in science and medicines in the EU. Find medicine Find information on centrally authorised medicines. What's new Find all new and updated information published on our website in one place.
FAQs Find answers to the most frequent asked questions we receive. Latest news. New combination of medicines to treat parasitic worm infections. New Chikungunya vaccine for adolescents from 12 and adults. The review of Vimkunya was expedited because of public health interest. One Health: EU agencies unite to tackle azole fungicide resistance in Aspergillus fungi. Events 10 Feb European Medicines Agency, Amsterdam, the Netherlands.
